Key facts
- · Type: Amendment first sale 2025-02-17 · Amount sold: $840K · Total offering: $2.37M · SEC filing
- · Type: New offering first sale 2025-02-17 · Amount sold: $200K · Total offering: $1M · SEC filing
- · Type: New offering first sale 2023-09-14 · Amount sold: $5K · Total offering: $5K · SEC filing
- · Type: New offering first sale 2023-09-08 · Amount sold: $10K · Total offering: $10K · SEC filing
Is EnZeta Immunotherapies, Inc. a real, registered company?
EnZeta Immunotherapies, Inc. is a registered filer with the SEC (CIK 1994145) and has filed since 2023-09-26. 4 filings are on record, the latest on 2026-03-06.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has EnZeta Immunotherapies, Inc. raised?
Its new offerings report $215K sold across 3 offerings, as its own filings state.
Run the free check on EnZeta Immunotherapies, Inc. →
CORAL GABLES, FLORIDA
2023
Biotechnology
4
$215K
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-03-06 | Amendment first sale 2025-02-17 | $840K | $2.37M | SEC filing |
| 2025-02-20 | New offering first sale 2025-02-17 | $200K | $1M | SEC filing |
| 2023-09-29 | New offering first sale 2023-09-14 | $5K | $5K | SEC filing |
| 2023-09-26 | New offering first sale 2023-09-08 | $10K | $10K | SEC filing |
Watch EnZeta Immunotherapies, Inc.
Get an email when EnZeta Immunotherapies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with EnZeta Immunotherapies, Inc.?
Who to contact
- Paul Kelly — Executive Officer, Director
- Sergio Traversa — Director
- Round: Form D/A (amended) filed 2026-03-06
- Amount sold: $840K
- Industry: Biotechnology
- Founded: 2023
- Based: CORAL GABLES, FLORIDA
People listed
- Paul Kelly — Executive Officer, Director
- Sergio Traversa — Director
- Filing: Form D/A (amended) filed 2026-03-06
- Amount sold: $840K
- Industry group: Biotechnology
- Year formed: 2023
- Based: CORAL GABLES, FLORIDA
- Entity type: Corporation
We'll show it in your MentionFox inbox when EnZeta Immunotherapies, Inc. raises, hires or launches. No email unless you switch it on.
Watch EnZeta Immunotherapies, Inc. →Want the whole picture on EnZeta Immunotherapies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on EnZeta Immunotherapies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on EnZeta Immunotherapies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from EnZeta Immunotherapies, Inc.'s own filings with the SEC. The people those filings name are on the team page.